Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients when targeted drugs fail

NCT ID NCT06868836

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen May 23, 2026 · Last updated Jun 13, 2026 · Updated 5 times

Summary

This study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow and hide from the immune system. It is given together with chemotherapy or another experimental drug (JS212) to people with advanced non-small cell lung cancer whose tumors have specific gene changes and no longer respond to targeted therapy (TKIs). About 78 participants will receive treatment every 3 weeks to see if the combination can shrink tumors and how safe it is.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provicial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510080, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

NON-SQUAMOUS NON-SMALL CELL LUNG CANCER